The serious drawbacks of the conventional treatment of pancreatic ductal adenocarcinoma
(PDAC) such as nonspecific toxicity and high resistance to chemo and radiation therapy,
have prompted the development and application of countless small interfering RNA (siRNA)‐
based therapeutics. Recent advances in drug delivery systems hold great promise for
improving siRNA‐based therapeutics and developing a new class of drugs, known as nano‐
siRNA drugs. However, many fundamental questions, regarding toxicity, immunostimulation …

The serious drawbacks of conventional pancreatic ductal adenocarcinoma (PDAC) therapy
like nonspecific toxicity and high resistance to chemo and radiation therapy, prompted the
development and application of countless siRNA-based therapeutics. Significant
technological success has been achieved in this area; however, the major challenges to
siRNA-based therapeutics becoming a new paradigm in the pancreatic cancer therapy stem
from enzymatic digestion, off-target effects, difficulty to enter cells, induction of innate …